» Articles » PMID: 24853089

Development of SLE Among "potential SLE" Patients Seen in Consultation: Long-term Follow-up

Overview
Publisher Wiley
Specialty General Medicine
Date 2014 May 24
PMID 24853089
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To identify factors associated with development of systemic lupus erythematosus (SLE) among patients evaluated at a tertiary care Lupus Center for potential SLE.

Methods: We identified patients first seen at the Brigham and Women's Hospital Lupus Center between 1 January 1992 and 31 December 2012 and thought to have potential SLE by a board-certified rheumatologist. All had 1-3 SLE ACR criteria at initial visit and > 2 follow-up visits ≥ 3 months apart. We reviewed medical records through 15 May 2013 for: SLE signs and symptoms, autoimmune serologies, prescriptions and diagnoses by board-certified rheumatologists. Bivariable analyses and multivariable logistic regression models were used to identify independent predictors of developing SLE.

Results: Two hundred and sixty four patients met inclusion criteria. At initial visit, mean age was 39.2 (SD 12.4) years, 94% were female and 67% white. Mean number of SLE ACR criteria was 2.7 (SD 1.0) and 88% were antinuclear antibody (ANA) positive at initial consultation. Mean follow-up time was 6.3 (SD 4.3) years and 67% were prescribed hydroxychloroquine in follow-up. At most recent visit, 56 (21%) had been diagnosed with SLE; 47 (18%) were thought not to have SLE and 161 (61%) were still considered to have potential SLE. In multivariable regression models, oral ulcers (OR 2.40, 95% CI 1.03-5.58), anti-dsDNA (OR 2.59, 95% CI 1.25-5.35) and baseline proteinuria or cellular casts (OR 16.20, 95% CI 1.63-161.02) were independent predictors of developing SLE. The most common other final diagnoses included fibromyalgia, Sjögren's syndrome, mixed connective tissue disease and cutaneous lupus.

Conclusion: Among patients with potential SLE at initial consultation, 21% were diagnosed with definite SLE within 6.3 years. Oral ulcers, anti-dsDNA and proteinuria or cellular casts were independent predictors of developing definite SLE. A better means of accurately identifying those who will develop SLE among those presenting with potential disease is necessary.

Citing Articles

Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies.

Li X, Li Y, Huang C, Liu J, Liu R, Zhang Z Ann Med. 2024; 56(1):2392882.

PMID: 39155852 PMC: 11334742. DOI: 10.1080/07853890.2024.2392882.


Genetic load in incomplete lupus erythematosus.

Slief M, Kheir J, Smith M, Mowery C, Macwana S, DeJager W Lupus Sci Med. 2023; 10(1.

PMID: 36599633 PMC: 9815005. DOI: 10.1136/lupus-2022-000843.


Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases.

Calderon L, Pope J Front Immunol. 2022; 13:869172.

PMID: 35603174 PMC: 9118990. DOI: 10.3389/fimmu.2022.869172.


The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives.

Sternhagen E, Bettendorf B, Lenert A, Lenert P J Inflamm Res. 2022; 15:1133-1145.

PMID: 35210816 PMC: 8863324. DOI: 10.2147/JIR.S275043.


Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.

Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G Nat Rev Rheumatol. 2021; 18(1):9-21.

PMID: 34764455 DOI: 10.1038/s41584-021-00710-2.


References
1.
Danieli M, Fraticelli P, Salvi A, Gabrielli A, Danieli G . Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol. 1998; 17(3):195-201. DOI: 10.1007/BF01451046. View

2.
Heinlen L, McClain M, Merrill J, Akbarali Y, Edgerton C, Harley J . Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007; 56(7):2344-51. DOI: 10.1002/art.22665. View

3.
Mosca M, Tani C, Neri C, Craig F, Della Rossa A, Baldini C . [Analysis of the evolution to defined connective tissue diseases of patients with "early unidifferentiated connective tissue diseases (UCTD)"]. Reumatismo. 2008; 60(1):35-40. DOI: 10.4081/reumatismo.2008.35. View

4.
Panush R, Greer J, Morshedian K . What is lupus? What is not lupus?. Rheum Dis Clin North Am. 1993; 19(1):223-34. View

5.
Li Q, Zhou J, Wandstrat A, Carr-Johnson F, Branch V, Karp D . Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2006; 147(1):60-70. PMC: 1810453. DOI: 10.1111/j.1365-2249.2006.03251.x. View